[{"id":"924f441f-af1d-4089-89c9-8c65da31f6a6","acronym":"NCI-2021-12428","url":"https://clinicaltrials.gov/study/NCT05183828","created_at":"2022-01-11T17:56:17.517Z","updated_at":"2024-07-02T16:35:05.369Z","phase":"Phase 4","brief_title":"Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer","source_id_and_acronym":"NCT05183828 - NCI-2021-12428","lead_sponsor":"University of Washington","biomarkers":" HER-2 • ER • AR • HSD3B1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • AR • HSD3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/23/2022","start_date":" 01/23/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-07"},{"id":"f399d23b-7387-4d29-af04-b8eeed6c99e9","acronym":"Maverick","url":"https://clinicaltrials.gov/study/NCT05361915","created_at":"2022-05-05T16:54:04.575Z","updated_at":"2024-07-02T16:35:14.341Z","phase":"Phase 2","brief_title":"Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT05361915 - Maverick","lead_sponsor":"Sorrento Therapeutics, Inc.","biomarkers":" HSD3B1","pipe":"","alterations":" ","tags":["HSD3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • Fujovee (abivertinib)"],"overall_status":"Suspended","enrollment":" Enrollment 100","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2024-03-18"},{"id":"5edcf750-2efe-4fff-8613-fe4db76a5f90","acronym":"","url":"https://clinicaltrials.gov/study/NCT02770391","created_at":"2021-01-20T21:52:08.137Z","updated_at":"2024-07-02T16:36:08.521Z","phase":"Phase 2","brief_title":"Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer","source_id_and_acronym":"NCT02770391","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" TMPRSS2 • HSD3B1 • FKBP5 • UBE2C","pipe":"","alterations":" ","tags":["TMPRSS2 • HSD3B1 • FKBP5 • UBE2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide • leuprolide acetate for depot suspension"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 10/17/2016","start_date":" 10/17/2016","primary_txt":" Primary completion: 04/29/2020","primary_completion_date":" 04/29/2020","study_txt":" Completion: 04/29/2020","study_completion_date":" 04/29/2020","last_update_posted":"2022-06-21"},{"id":"af2ca646-b71d-4b28-aa4e-b1494c15df54","acronym":"EXPLORE","url":"https://clinicaltrials.gov/study/NCT04268628","created_at":"2021-01-20T21:59:58.049Z","updated_at":"2024-07-02T16:36:19.009Z","phase":"","brief_title":"A Study of Pharmacodynamic and Genetic Parameters of Abira-DES Study Participants (NCT02217566) - Participants With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Following Unresponsive Treatment With Diethylstilbestrol","source_id_and_acronym":"NCT04268628 - EXPLORE","lead_sponsor":"Janssen-Cilag Farmaceutica Ltda.","biomarkers":" HSD3B1","pipe":"","alterations":" ","tags":["HSD3B1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 03/19/2020","start_date":" 03/19/2020","primary_txt":" Primary completion: 11/16/2020","primary_completion_date":" 11/16/2020","study_txt":" Completion: 11/16/2020","study_completion_date":" 11/16/2020","last_update_posted":"2021-12-31"},{"id":"3104391b-e3f1-42cd-bf6a-12a8612992d6","acronym":"CUARTET","url":"https://clinicaltrials.gov/study/NCT04601441","created_at":"2021-01-19T20:30:33.227Z","updated_at":"2024-07-02T16:36:37.659Z","phase":"Phase 4","brief_title":"Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan","source_id_and_acronym":"NCT04601441 - CUARTET","lead_sponsor":"Kindai University","biomarkers":" KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1","pipe":"","alterations":" ","tags":["KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2020-12-08"}]